問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Colorectal Surgery

Division of General Surgery

Digestive System Department

China Medical University Hospital-Taipei (在職)

Division of Hematology & Oncology

Taipei Veterans General Hospital

更新時間：2023-09-19

邱昌芳Chiu, Chang-Fang
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

99Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱昌芳

List

192Cases

2020-09-20 - 2024-02-22

Phase I

A Phase I, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-866/OBI-821, a Novel Anti-Stage-Specific Embryonic Antigen-4 (SSEA-4) Active Immunotherapy, in Patients with Advanced/Metastatic Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Condition/Disease

    Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

  • Test Drug

    OBI-866 (SSEA-4) / OBI-821 (adjuvant)

Participate Sites
2Sites

Recruiting2Sites

白禮源
China Medical University Hospital

Division of Hematology & Oncology

2020-08-01 - 2022-08-31

Phase I/II

A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.

  • Condition/Disease

    Metastatic Solid Tumors / Locally Advanced Solid Tumors

  • Test Drug

    OBI 888

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2014-03-15 - 2017-12-31

Phase II

A PHASE 2, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS OF THE ANTI-ALK-1 MAB PF-03446962 IN COMBINATION WITH BEST SUPPORTIVE CARE VS. BEST SUPPORTIVE CARE ALONE IN ADULT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    PF-03446962 injection

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2007-07-02 - 2012-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2009-10-01 - 2012-01-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2011-04-15 - 2013-03-31

Phase I

A phase I dose escalation trial of weekly intravenous administrations of BI 836845 in patients with advanced solid cancers with repeated administrations in patients showing clinical benefit

  • Condition/Disease

    advanced solid cancer

  • Test Drug

    BI 836845

Participate Sites
3Sites

Terminated3Sites

2019-11-30 - 2024-07-31

Phase III

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mLOPDIVO (nivolumab) Injection 10mg/mLYERVOY (ipilimumab) Injection 5mg/mLYERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
9Sites

Recruiting9Sites

2020-06-30 - 2023-12-12

Phase III

A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Intermediate-stage Hepatocellular Carcinoma (HCC)

  • Test Drug

    Ipilimumab (5mg/mL; 40 ml)、 nivolumab (10mg/mL; 10 ml)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2020-03-01 - 2021-12-31

Phase I

A Phase I Safety and Pharmacokinetic Study of CVM-1118 Extended-Release Capsules Administered Orally to Patients with Advanced Cancers

  • Condition/Disease

    Advanced Cancer

  • Test Drug

    CVM-1118 ER Capsule

Participate Sites
2Sites

Recruiting2Sites

1 16 17 18 19 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB